Santen Pharmaceutical (OTCMKTS:SNPHY) Updates FY 2024 Earnings Guidance

Santen Pharmaceutical (OTCMKTS:SNPHY) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 0.770-0.770 for the period. The company issued revenue guidance of $2.0 billion-$2.0 billion.

Santen Pharmaceutical Trading Down 1.0 %

SNPHY stock traded down $0.10 on Friday, hitting $9.81. The company had a trading volume of 15,096 shares, compared to its average volume of 17,392. Santen Pharmaceutical has a 12-month low of $8.95 and a 12-month high of $13.00. The stock’s 50-day simple moving average is $10.34 and its 200 day simple moving average is $11.32.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.